本文選題：溫敏凝膠 + 眼用制劑��； 參考：《中國醫(yī)院藥學(xué)雜志》2015年24期

【摘要】：目的:篩選馬來酸噻嗎洛爾眼用溫敏型凝膠優(yōu)化處方,并對其體外釋放進行評價。方法:選用泊洛沙姆P407、P188為載體材料制備眼用溫敏凝膠,測定不同處方的凝膠前體溶液分別在未經(jīng)處理和經(jīng)人工淚液稀釋條件下,從溶液態(tài)轉(zhuǎn)變?yōu)槟z態(tài)的膠凝溫度,通過星點設(shè)計-效應(yīng)面法篩選優(yōu)化處方,并考察膠凝時間和釋放行為。結(jié)果:根據(jù)溫敏凝膠保存和使用的溫度要求,篩選出優(yōu)化處方為P407∶P188(24.25%∶1.56%)。前體溶液能夠在34℃人工淚液中迅速形成凝膠,并在體外緩慢釋放6 h以上。結(jié)論:經(jīng)過篩選并制備出的噻嗎洛爾溫敏型凝膠具有良好的載藥能力、穩(wěn)定性及釋放性能,滿足眼用制劑質(zhì)量要求和實際應(yīng)用要求。
[Abstract]:Aim: to optimize the formulation of tiamolol maleate ophthalmic gel and evaluate its release in vitro. Methods: Poloxamer P407 P188 was used as carrier material to prepare ophthalmic thermo-sensitive gel. The gelation temperature of precursor solution of different prescriptions was determined from solution state to gel state under untreated and artificial tear dilution conditions, respectively. The optimized formulation was screened by star design-effect surface method, and the gelation time and release behavior were investigated. Results: according to the temperature requirement of preservation and use of thermo-sensitive gel, the optimized prescription was selected as P407: P1880.24.25: 1.56. The precursor solution was able to form gel rapidly in artificial tear at 34 鈩，

本文編號：1967049